Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Authors: Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu - The Lancet 2020 cited by 1,075